Nektar Therapeutics (NKTR) Reveals an Earnings Mystery – News Heater
Home  »  Companies   »  Nektar Therapeutics (NKTR) Reveals an Earnings Mys...

Nektar Therapeutics (NKTR) Reveals an Earnings Mystery

Nektar Therapeutics (NASDAQ:NKTR) went up by 4.63% from its latest closing price compared to the recent 1-year high of $19.37. The company’s stock price has collected 17.43% of gains in the last five trading sessions. The Wall Street Journal reported on 05/11/22 that This Biotech Flew High, Then Fell Hard When Its Cancer Drug Failed

Is It Worth Investing in Nektar Therapeutics (NASDAQ :NKTR) Right Now?

Plus, the 36-month beta value for NKTR is at 1.27. Opinions of the stock are interesting as 1 analysts out of 13 who provided ratings for Nektar Therapeutics declared the stock was a “buy,” while 0 rated the stock as “overweight,” 10 rated it as “hold,” and 1 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $4.70, which is $0.86 above the current price. NKTR currently public float of 184.21M and currently shorts hold a 9.69% ratio of that float. Today, the average trading volume of NKTR was 3.71M shares.

NKTR’s Market Performance

NKTR stocks went up by 17.43% for the week, with a monthly drop of -1.03% and a quarterly performance of -36.84%, while its annual performance rate touched -76.96%. The volatility ratio for the week stands at 8.54% while the volatility levels for the past 30 days are set at 7.49% for Nektar Therapeutics. The simple moving average for the period of the last 20 days is 10.25% for NKTR stocks with a simple moving average of -63.31% for the last 200 days.

Analysts’ Opinion of NKTR

Many brokerage firms have already submitted their reports for NKTR stocks, with Jefferies repeating the rating for NKTR by listing it as a “Hold.” The predicted price for NKTR in the upcoming period, according to Jefferies is $4 based on the research report published on May 31st of the current year 2022.

Goldman, on the other hand, stated in their research note that they expect to see NKTR reach a price target of $3. The rating they have provided for NKTR stocks is “Sell” according to the report published on April 18th, 2022.

Mizuho gave a rating of “Neutral” to NKTR, setting the target price at $8 in the report published on March 15th of the current year.

NKTR Trading at -6.03% from the 50-Day Moving Average

After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.18% of loss for the given period.

Volatility was left at 7.49%, however, over the last 30 days, the volatility rate increased by 8.54%, as shares surge +7.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.31% lower at present.

During the last 5 trading sessions, NKTR rose by +17.43%, which changed the moving average for the period of 200-days by -75.80% in comparison to the 20-day moving average, which settled at $3.50. In addition, Nektar Therapeutics saw -71.58% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at NKTR starting from ROBIN HOWARD W, who sale 36,529 shares at the price of $3.95 back on May 16. After this action, ROBIN HOWARD W now owns 620,941 shares of Nektar Therapeutics, valued at $144,290 using the latest closing price.

NORTHCOTT JOHN, the SVP & Chief Commercial Officer of Nektar Therapeutics, sale 4,592 shares at $3.95 during a trade that took place back on May 16, which means that NORTHCOTT JOHN is holding 223,210 shares at $18,138 based on the most recent closing price.

Stock Fundamentals for NKTR

Current profitability levels for the company are sitting at:

  • -437.76 for the present operating margin
  • +65.93 for the gross margin

The net margin for Nektar Therapeutics stands at -514.03. Equity return is now at value -65.60, with -41.00 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 9.34.